
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

72969
10.1038/s41598-024-72969-w
Article
Association between triglyceride glucose-body mass index and all-cause mortality in critically ill patients with acute pancreatitis
Zhu Yang 12
Li Ye 3
Li Xuan 3
Huang Sheng 3
Li Yihui 13423763712@163.com

12
1 https://ror.org/053w1zy07 grid.411427.5 0000 0001 0089 3695 Department of General Surgery, The Second Affiliated Hospital of Hunan Normal University, Changsha, 410008 Hunan People’s Republic of China
2 Department of General Surgery, No. 921 Hospital of the PLA Joint Logistic Support Force, Changsha, 410008 Hunan People’s Republic of China
3 grid.216417.7 0000 0001 0379 7164 National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008 Hunan People’s Republic of China
16 9 2024
16 9 2024
2024
14 216057 6 2024
12 9 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
This study delves into the correlation between the triglyceride glucose-body mass index (TyG-BMI) index upon hospital admission and clinical outcomes among this patient population. We investigated the association between TyG-BMI at hospital admission and clinical outcomes in this patient group, and analyzed data from the Medical Information Mart for Intensive Care IV database, identifying acute pancreatitis (AP) patients admitted to ICUs and stratifying them by TyG-BMI quartiles. We assessed the relationship between TyG-BMI and mortality (both in-hospital and ICU) using Cox proportional hazards regression and restricted cubic splines. The cohort included 419 patients, average age 56.34 ± 16.62 years, with a majority being male (61.58%). Hospital and ICU mortality rates were 11.93% and 7.16%, respectively. Higher TyG-BMI was positively correlated with increased all-cause mortality. Patients in the highest TyG-BMI quartile had significantly greater risks of in-hospital and ICU mortality. An S-shaped curve in the spline analysis indicated a threshold effect at a TyG-BMI of 243 for increased in-hospital mortality risk. TyG-BMI is a reliable predictor of both in-hospital and ICU mortality in severely ill AP patients, suggesting its utility in enhancing risk assessment and guiding clinical interventions for this vulnerable population.

Keywords

Acute pancreatitis
Triglyceride glucose-body mass index (TyG-BMI)
All-cause mortality
Insulin resistance
MIMIC-IV
Subject terms

Acute pancreatitis
Dyslipidaemias
issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Pancreatitis represents a primary cause of hospitalization among patients with gastrointestinal disorders, entailing substantial morbidity, mortality, and socioeconomic burdens1,2. It also assumes a significant role in escalating hospital mortality3. Roughly one in five patients develop moderate to severe acute pancreatitis (AP), triggering severe complications such as necrosis of pancreatic or surrounding tissues and failure of multiple organs. Reported mortality rates fluctuate between 20% and 40%4,5, underscoring the urgency of promptly evaluating AP severity and implementing interventions. There are several scoring systems available to evaluate AP severity, such as Ranson criteria6, Acute Physiology and Chronic Health Evaluation II (APACHE-II)6, Balthazar grade7, and Bedside Index for Severity in Acute Pancreatitis (BISAP)8. These scoring systems typically involve a more complex assessment process that requires gathering multiple indicators. This time-consuming assessment process may lead to potential delays in identifying the optimal treatment window, thereby increasing the risk of mortality in certain patients. Thus, it is urgent to identify a simplistic, cost-efficient, and acutely sensitive predictive marker for the severity of AP.

Insulin resistance (IR) is a condition in which insulin becomes less effective in facilitating the uptake and utilization of glucose9. This condition is closely associated with the development of AP and is a significant risk factor for its progression10. The triglyceride-glucose (TyG) index, which is derived from fasting triglyceride (TG) and blood glucose (FBG) levels, has emerged as a simple surrogate marker for IR11.

Obesity, as measured by body mass index (BMI), plays a pivotal role in the development of IR, and stands as a critical determinant in its etiology12. The TyG-BMI composite index, a fusion of TyG and BMI, has shown commendable agreement with the homeostatic model assessment of IR in measuring IR in Korean9 and Chinese cohorts13. The predictive role of TyG-BMI index has been demonstrated in various clinical conditions, such as ischemic stroke14, heart failure15, and the necessity of percutaneous coronary intervention16. We hypothesize that this index is associated with prognostic outcomes in patients afflicted with AP and could potentially be utilized for early prognostic assessment. While the prognostic implications of the TyG-BMI index have been studied across a spectrum of diseases, its impact on clinical endpoints within the AP patient population has not yet been fully investigated. Therefore, the aim of our study is to ascertain the relationship between TyG-BMI and mortality in AP patients.

Methods

Database

We harnessed clinical data from the Medical Information Mart for Intensive Care (MIMIC)-IV database, an international online intensive care repository. The database contains patient-related information from the Intensive Care Units (ICUs) of Beth Israel Deaconess Medical Center from 2008 to 2019. It comprises detailed records of 299,712 hospitalized patients and 73,181 critical care patients. In our research team, the author Y.L. has completed the Collaborative Institutional Training Initiative program, (certification number 53244021).

Study population and definitions

Data extraction was conducted utilizing Structured Query Language within a PostgreSQL environment (version 14.6). Based on our analysis of the MIMIC-IV database17, ICU admission is generally determined by the actual care received by patients, typically including those with hemodynamic instability, respiratory failure requiring mechanical ventilation, or other organ dysfunctions necessitating close monitoring and support. AP was diagnosed by the International Classification of Disease, 9th Revision (ICD-9) code 577.0 or 10th Revision (ICD-10) code K85. in patients aged over 18 years. Patients lacking recorded admission-day levels of FBG, TG, or BMI were excluded. The methodological flowchart is depicted in Fig. 1.

Fig. 1 Flowchart of participants through the trial.

Data collection

The TyG-BMI index was designated as the primary variable of this investigation. Baseline characteristics of patients were extracted from the database, encompassing demographics such as age, sex, ethnicity, marital status, and BMI. We also collected the Simplified Acute Physiology Score II (SAPS II) at admission and the administration details of Vasopressin and Octreotide. The SAPS II, used for severity assessment, consists of 17 variables including physiological measurements, age, and admission type. Higher scores indicate greater severity and higher predicted mortality18. SAPS II is widely used for assessing severity in critically ill patients, including those with AP19. Comorbidities at baseline, including chronic lung disease, hypertension, acute kidney injury (AKI), heart failure, diabetes, and malignancy, were collected. Pertinent laboratory parameters at ICU admission were also gathered, encompassing red blood cell distribution width, red blood cell (RBC) count, white blood cell (WBC) count, platelet count, alanine aminotransferase (ALT) levels, blood glucose, hemoglobin concentration, creatinine, lactate, international normalized ratio, blood urea nitrogen, anion gap, serum chloride levels, potassium levels, sodium levels, and total bilirubin levels. To reduce potential biases, variables with over 15% missing values were excluded from the analysis. The “mice” package in the R software was used for processing missing data.

Definition and clinical outcomes

The TyG-BMI index was calculated using the following equation: In [TG (mg/dL) × FBG (mg/dL)/2] × BMI16. The primary endpoint was all-cause mortality during hospitalization, while the secondary endpoint was ICU mortality.

Statistical analysis

Continuous variables are presented as mean ± SD or median (interquartile range), depending on their distribution. Meanwhile, categorical variables were displayed as proportions. The Kolmogorov-Smirnov test was used for testing the normality of continuous data. Normally distributed variables were analyzed utilizing t-test or ANOVA, while the Mann-Whitney U-test and Kruskal-Wallis test were reserved for non-normally distributed variables.

To investigate the effect of the TyG-BMI index on short-term survival, Kaplan-Meier survival analysis was executed to ascertain 28-day and 90-day all-cause mortality in patients with different TyG-BMI levels, and log-rank testing was used for comparisons between groups. The relation between the TyG-BMI index and mortality was further explored through univariate and multivariate Cox regression analyses. Model 1 served as the unadjusted reference; Model 2 was adjusted for demographic variables including age, sex, and ethnicity. Model 3 was additionally adjusted for a comprehensive range of clinical covariates such as comorbidities (heart failure, AKI, hypertension, diabetes, sepsis, chronic obstructive pulmonary disease, and malignancies), hematologic and biochemical parameters (WBC, RBC, platelet count, ALT levels), metabolic and physiologic data (serum lactate, creatinine, total bilirubin, anion gap), SAPS II, and specific treatments (Vasopressin and Octreotide administration). The Cox regression analysis and a restricted cubic spline model with four knots were leveraged to ascertain the link between TyG-BMI index and the risk of in-hospital and ICU mortality in critically ill patients with AP. All statistical analyses were carried out using the R software, version 4.0.2.

Results

This investigation incorporated 419 patients admitted for severe AP. The median age of these patients was 56.34 years, and male patients constituted 61.58%. The median value of the TyG-BMI of the participants was 297.88. The in-hospital and ICU mortality rates were 11.93% and 7.16% respectively, as detailed in Table 1.

Table 1 Baseline characteristics of acute pancreatitis patients grouped according to TyG-BMI index quartile.

Categories	Overall
(N = 419)	Q1
(N = 105)	Q2
(N = 105)	Q3
(N = 104)	Q4
(N = 105)	P-value	
Demographic	
 Age, years	56.34 ± 16.62	60.72 ± 18.38	56.46 ± 16.99	53.59 ± 15.65	54.57 ± 14.51	0.010	
 Male, n (%)	258 (61.58)	55 (52.38)	65 (61.90)	65 (62.50)	73 (69.52)	0.086	
Ethnicity, n (%)	0.983	
 White	282 (67.3)	69 (65.71)	70 (66.67)	71 (68.27)	72 (68.57)		
 Black	32 (7.64)	9 (8.57)	8 (7.62)	6 (5.77)	9 (8.57)		
 Other	105 (25.06)	27 (25.71)	27 (25.71)	27 (25.96)	24 (22.86)		
BMI, kg/m2, mean ± SD	30.78 ± 7.31	24.70 ± 3.86	29.41 ± 5.78	31.62 ± 5.31	37.40 ± 7.37	< 0.001	
Marital status (%)	0.578	
 Married	189 (45.11)	43 (40.95)	46 (43.81)	48 (46.15)	52 (49.52)		
 Single	161 (38.42)	39 (37.14)	40 (38.10)	41 (39.42)	41 (39.05)		
 Divorced	40 (9.55)	11 (10.48)	12 (11.43)	8 (7.69)	9 (8.57)		
 Other	29 (6.92)	12 (11.43)	7 (6.67)	7 (6.73)	3 (2.86)		
Laboratory tests	
 RBC, m/µL, mean ± SD	3.77 ± 0.88	3.68 ± 0.87	3.79 ± 0.84	3.58 ± 0.87	4.04 ± 0.90	0.001	
 WBC, K/µL, mean ± SD	14.46 ± 8.80	13.63 ± 9.24	15.28 ± 9.97	14.46 ± 7.93	14.46 ± 7.91	0.605	
 Platelet, K/µL, mean ± SD	220.20 ± 132.33	211.02 ± 125.14	233.19 ± 132.93	220.10 ± 149.09	216.50 ± 121.50	0.661	
 Hemoglobin, g/dL, mean ± SD	11.53 ± 2.57	11.22 ± 2.67	11.66 ± 2.40	10.98 ± 2.65	12.27 ± 2.40	0.001	
 Glucose, mg/dL, mean ± SD	159.60 ± 111.63	137.86 ± 159.40	145.62 ± 60.75	162.49 ± 87.44	192.47 ± 107.89	0.002	
 TG, mg/dL, mean ± SD	482.80 ± 1106.02	160.00 ± 245.59	288.02 ± 614.79	482.12 ± 1173.05	1001.07 ± 1643.44	< 0.001	
 Creatinine, mg/dL, mean ± SD	1.64 ± 1.73	1.44 ± 1.65	1.26 ± 1.38	1.81 ± 1.82	2.06 ± 1.91	0.003	
 ALT, IU/L, mean ± SD	395.84 ± 1626.18	627.93 ± 2302.70	350.20 ± 1493.74	435.72 ± 1703.61	169.87 ± 333.07	0.230	
 Albumin, g/dL, mean ± SD	2.90 ± 0.62	2.97 ± 0.68	2.97 ± 0.61	2.87 ± 0.61	2.80 ± 0.58	0.117	
 Sodium, mEq/L, mean ± SD	138.10 ± 5.97	138.17 ± 5.48	138.49 ± 5.20	137.57 ± 6.71	138.15 ± 6.42	0.733	
 Potassium, mEq/L, mean ± SD	4.15 ± 0.80	4.13 ± 0.88	3.96 ± 0.66	4.16 ± 0.91	4.33 ± 0.69	0.009	
 Calcium, mg/dl, mean ± SD	104.36 ± 7.27	103.99 ± 6.59	104.20 ± 6.65	104.18 ± 8.57	105.07 ± 7.18	0.713	
 INR, mean ± SD	1.52 ± 0.94	1.73 ± 1.38	1.45 ± 0.88	1.47 ± 0.67	1.44 ± 0.63	0.079	
 Bilirubin, total, mg/dL, mean ± SD	1.52 ± 0.94	1.73 ± 1.38	1.45 ± 0.88	1.47 ± 0.67	1.44 ± 0.63	0.079	
 RDW	14.81 ± 1.74	15.02 ± 1.77	14.50 ± 1.58	15.00 ± 1.94	14.70 ± 1.62	0.092	
 Aniongap, mean ± SD	15.96 ± 4.94	15.76 ± 5.11	16.12 ± 4.53	16.05 ± 5.08	15.92 ± 5.10	0.956	
 Lactate, mean ± SD	2.31 ± 1.91	2.46 ± 2.40	2.07 ± 1.24	2.11 ± 1.34	2.60 ± 2.31	0.120	
 TyG index	9.60 ± 1.21	8.80 ± 0.83	9.32 ± 0.89	9.81 ± 1.01	10.49 ± 1.35	< 0.001	
 TyG-BMI index	297.88 ± 83.41	207.07 ± 27.76	260.71 ± 10.24	310.05 ± 18.48	413.83 ± 57.48	< 0.001	
Comorbidities	
 Hypertension, n, %	188 (44.87)	38 (36.19)	46 (43.81)	49 (47.12)	55 (52.38)	0.119	
 Diabetes, n, %	123 (29.36)	15 (14.29)	24 (22.86)	37 (35.58)	47 (44.76)	< 0.001	
 HF, n (%)	52 (12.41)	15 (14.29)	11 (10.48)	10 (9.62)	16 (15.24)	0.528	
 AKI, n (%)	270 (64.44)	59 (56.19)	58 (55.24)	74 (71.15)	79 (75.24)	0.002	
 COPD, n (%)	16 (3.82)	7 (6.67)	2 (1.90)	5 (4.81)	2 (1.90)	0.218	
 MT, n, %	28 (6.68)	13 (12.38)	5 (4.76)	6 (5.77)	4 (3.81)	0.055	
 Sepsis, n, (%)	279 (66.59)	67 (63.81)	61 (58.10)	73 (70.19)	78 (74.29)	0.067	
Medicine	
 Vasopressin	94 (22.43)	19 (18.10)	21 (20.00)	29 (27.88)	25 (23.81)	0.336	
 Octreotide	36 (8.59)	11 (10.48)	7 (6.67)	11 (10.58)	7 (6.67)	0.575	
SAPSII, mean ± SD	36.61 ± 16.35	36.26 ± 16.07	33.17 ± 15.12	37.23 ± 16.21	39.80 ± 17.44	0.031	
Events	
 Hospital mortality	50 (11.93)	12 (11.43)	7 (6.67)	19 (18.27)	12 (11.43)	0.079	
 ICU mortality	30 (7.16)	9 (8.57)	4 (3.81)	10 (9.62)	7 (6.67)	0.381	
*TyG-BMI index: Q1 (134.91-241.68), Q2 (241.68-281.39), Q3 (281.39-349.13), Q4 (349.13-683.47).

TyG-BMI index triglyceride glucose-body mass index, BMI body mass index, RBC red blood cell, WBC white blood cell, TG triglyceride, ALT alanine aminotransferase, RDW red blood cell distribution width, INR malignant tumor, TyG triglyceride-glucose, HF heart failure, MT malignant tumor, COPD chronic obstructive pulmonary disease, AKI acute kidney injury, SAPS II Simplified Acute Physiology Score II, ICU malignant tumor.

Baseline characteristics

The patients were classified into quartiles by the level of the TyG-BMI index [quartile 1 (134.91-241.68), quartile 2 (241.68-281.39), quartile 3 (281.39-349.13), quartile 4 (349.13-683.47)], as shown in Table 1. Individuals with the uppermost quartile of the TyG-BMI index tended to be older and exhibited elevated SAPS II scores upon admission, increased prevalence of diabetes and AKI, as well as higher levels of RBC, hemoglobin, glucose, TG, creatinine, and potassium compared to individuals in lower quartiles. Despite these differences, the in-hospital and ICU mortality rates did not significantly diverge across quartiles (P > 0.05).

Kaplan–Meier analysis

Figure 2 illustrates Kaplan-Meier survival analysis curves assessing key outcomes among different TyG-BMI groups. Noteworthy, no significant disparities in mortality at 28 and 90 days were observed (log-rank P > 0.05).

Fig. 2 Kaplan–Meier survival analysis curves for all-cause mortality at 28 days (a), and 90 days (b).

Cox regression analysis

Cox proportional hazards regression was leveraged to scrutinize the correlation between the TyG-BMI and in-hospital and ICU mortality outcomes. The analytical findings showed that TyG-BMI is significantly associated with an increased risk of in-hospital mortality. This association was observed in all models: unadjusted [HR, 1.03; 95% CI: 1.01–1.06; P = 0.020], partially adjusted [HR, 1.04; 95% CI: 1.01–1.07; P = 0.014], and fully adjusted [HR, 1.05; 95% CI: 1.01–1.10; P = 0.010], when TyG-BMI was treated as a continuous variable. In addition, the index was identified as a significant risk factor for ICU mortality in AP patients in the fully adjusted model (HR: 1.10; 95% CI: 1.02–1.18; P = 0.017). The uppermost quartile of the TyG-BMI was correlated with a significant increase in the risk of in-hospital mortality [HR, 4.08; 95% CI: 1.34–12.41; P = 0.007] compared to the nadir quartile, as shown in the fully adjusted Cox regression (Table 2). similar results for ICU mortality were found in multivariate Cox regression analysis (Table 2).

Table 2 Cox proportional hazard ratios (HR) for all-cause mortality.

Categories	Model 1	Model 2	Model 3	
HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	
Hospital mortality	
 Continuous variable per 10 units	1.03 (1.01–1.06)	0.020	1.04 (1.01–1.07)	0.014	1.05 (1.01–1.10)	0.010	
 Quartile	
  Q1	Ref.		Ref.		Ref.		
  Q2	0.67 (0.26–1.71)	0.406	0.71 (0.28–1.81)	0.466	0.98 (0.30–3.24)	0.973	
  Q3	1.89 (0.92–3.89)	0.085	1.89 (0.90–3.97)	0.093	1.72 (0.61–4.85)	0.307	
  Q4	1.63 (0.73–3.64)	0.230	1.79 (0.79–4.07)	0.164	4.08 (1.34–12.41)	0.013	
ICU mortality	
 Continuous variable per 10 units	1.02 (0.99–1.06)	0.197	1.04 (0.99–1.09)	0.094	1.10 (1.02–1.18)	0.017	
 Quartile	
  Q1	Ref.		Ref.		Ref.		
  Q2	0.50 (0.15–1.64)	0.254	0.54 (0.16–1.78)	0.312	0.72 (0.16–3.24)	0.664	
  Q3	1.22 (0.50–3.01)	0.660	1.18 (0.46–2.98)	0.734	0.89 (0.23–3.46)	0.861	
  Q4	1.21 (0.45–3.25)	0.705	1.38 (0.49–3.83)	0.542	6.53 (1.13–37.84)	0.036	
*Model 1: Unadjusted model; †Model 2: adjusted for gender, age, race; ‡Model 3: adjusted for gender, age, race, heart failure, acute kidney injury, hypertension, diabetes, chronic pulmonary diseases, sepsis, malignant tumor, WBC, RBC, platelet, alanine aminotransferase, serum lactate, creatinine, total bilirubin, anion gap, SAPS II, the use of Vasopressin and Octreotide.

CI confidence interval, TyG-BMI triglyceride glucose-body mass index, HR hazard ratio.

Restricted cubic splines

The restricted cubic splines were employed to better characterize and graphically represent the relationship between the TyG-BMI index and in-hospital mortality. As illustrated in Fig. 3, a non-linear correlation was noted between TyG-BMI index and in-hospital mortality. Specifically, the mortality risk initially decreased within the lower spectrum of TyG-BMI, to a nadir at a TyG-BMI index value of approximately 243, and then elevated steeply (P for overall < 0.001, P for non-linearity = 0.003).

Fig. 3 Relationship between the TyG-BMI index and in-hospital mortality.

Discussion

The objective of this investigation was to scrutinize the correlation of TyG-BMI index with clinical prognoses amongst a demographic of acutely ill patients afflicted with AP. Following adjustment for confounders, our findings indicated that escalated TyG-BMI values were closely linked with an upsurge in all-cause mortality both within ICU settings and overall hospitalization among these individuals. As such, the TyG-BMI index might be instrumental as a prognostic indicator for healthcare providers, potentially serving as an independent marker of mortality in the context of AP. Our findings align with studies demonstrating the prognostic value of TyG-BMI in various clinical contexts. TyG-BMI has shown associations with cardiovascular outcomes20–22, stroke risk23,24, and mortality in critical care settings25,26. It has also been linked to coronary artery disease severity16,20 and long-term outcomes in heart failure21. Our study extends the utility of TyG-BMI to AP.

The pathogenic mechanisms underlying AP significantly involve inflammation within the peripancreatic adipose tissue27. IR, as a protracted, low-grade inflammatory state, is typified by heightened systemic concentrations of pro-inflammatory cytokines28,29. This increase in pro-inflammatory cytokines further intensifies inflammation following the initial trigger and magnifies damage to the pancreas and other organs, resulting in systemic inflammatory response syndrome, organ failure, and local complications. Obesity and diabetes, which serve as representative markers of metabolic disorders, have been strongly linked to the occurrence and progress of AP30,31. The association between TyG-BMI and mortality in our study could be attributed to its capture of both lipid metabolism and obesity32, which are crucial factors in the pathogenesis of AP33. Additionally, insulin resistance, reflected by TyG-BMI13,34, may exacerbate the inflammatory response in AP34.

IR is a pivotal contributor to the pathogenesis of type 2 diabetes mellitus, dyslipidemic disorders, adiposity, and cardiovascular pathologies35. Consequently, the TyG index was conceived as a substitute indicator for assessing IR36,37. Additionally, BMI is frequently utilized to evaluate obesity and its correlation with IR. A study utilizing data from the Korean National Health and Nutrition Examination Survey has shown that the TyG-BMI index exhibits superior accuracy in delineating IR compared to other metrics9. The TyG-BMI index has been recognized as an efficacious marker for assessing IR16, and stands as a prognostic element for ischemic cerebrovascular events, heart failure, and the necessity for percutaneous coronary intervention14–16. However, there is limited research on the prognostic value of TyG-BMI in determining the prognosis of patients with AP. To our knowledge, this is the inaugural analysis to probe the association of TyG-BMI index with in-hospital and ICU mortality in individuals with AP, using data from the MIMIC-IV database. Clinically, TyG-BMI could be a valuable tool for risk stratification in AP patients due to its simplicity and reliance on readily available parameters. However, further research is needed to establish optimal cut-off values and validate its use in diverse populations.

Nonetheless, our investigation has several limitations. Firstly, the study is a single-center, observational study, which hinders us from inferring causation. Secondly, due to the insufficient sample size, subgroup analysis was not conducted. We look forward to conducting subgroup analysis in a larger prospective study. Thirdly, TyG-BMI measurements were limited to the time of ICU admission in this study, and the changes during the course of hospitalization were not measured. Fourthly, there are limitations related to the MIMIC-IV database and our assessment tools. The database contains a mixture of ICD-9 and ICD-10 codes, with ICD-9 not specifying pancreatitis etiology, preventing consistent analysis of etiology for all cases. Additionally, while the SAPS II used for severity assessment is widely validated for critically ill patients, it may not capture some pancreatitis-specific factors. The database lacked variables required for pancreatitis-specific scoring systems, which might have provided more targeted prognostic information. Finally, due to the lack of longer follow-up data in the MIMIC-IV database, our study focuses solely on in-hospital and ICU mortality, which may have affected the overall prognostic assessment. Hence, additional studies are warranted to corroborate our observations.

Conclusion

Overall, our study reveals a significant association between higher TyG-BMI index and increased mortality in critically ill AP patients. This expands the index’s applicability to acute care settings and suggests its potential as a simple risk stratification tool. Future prospective, multi-center studies are needed to validate these findings, establish the index’s clinical utility, and explore its integration with established pancreatitis-specific scoring systems in AP management.

Author contributions

All authors contributed to the study conception and design. Yang Zhu was responsible for the initial drafting of the manuscript. Yang Zhu, Ye Li, Xuan Li, Sheng Huang, and Yihui Li participated in the material preparation, data collection, and analysis. All authors critically reviewed and provided feedback on previous versions of the manuscript. Yang Zhu made significant contributions to revising and finalizing the manuscript. All authors read and approved the final manuscript.

Data availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Competing interests

The authors declare no competing interests.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Goyal H Awad H Hu ZD Prognostic value of admission red blood cell distribution width in acute pancreatitis: a systematic review Ann. Transl Med. 2017 5 342 10.21037/atm.2017.06.61 28936436
Goyal, H., Awad, H. & Hu, Z. D. Prognostic value of admission red blood cell distribution width in acute pancreatitis: a systematic review. Ann. Transl Med. 5, 342. 10.21037/atm.2017.06.61 (2017).28936436 10.21037/atm.2017.06.61
2. Yadav D Lowenfels AB The epidemiology of pancreatitis and pancreatic cancer Gastroenterology 2013 144 1252 1261 10.1053/j.gastro.2013.01.068 23622135
Yadav, D. & Lowenfels, A. B. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology 144, 1252–1261. 10.1053/j.gastro.2013.01.068 (2013).23622135 10.1053/j.gastro.2013.01.068
3. Scurt FG Bose K Canbay A Mertens PR Chatzikyrkou C Acute kidney injury following acute pancreatitis (AP-AKI): definition, pathophysiology, diagnosis and therapy Z. Gastroenterol. 2020 58 1241 1266 10.1055/a-1255-3413 33291178
Scurt, F. G., Bose, K., Canbay, A., Mertens, P. R. & Chatzikyrkou, C. Acute kidney injury following acute pancreatitis (AP-AKI): definition, pathophysiology, diagnosis and therapy. Z. Gastroenterol. 58, 1241–1266. 10.1055/a-1255-3413 (2020).33291178 10.1055/a-1255-3413
4. Schepers NJ Impact of characteristics of organ failure and infected necrosis on mortality in necrotising pancreatitis Gut 2019 68 1044 1051 10.1136/gutjnl-2017-314657 29950344
Schepers, N. J. et al. Impact of characteristics of organ failure and infected necrosis on mortality in necrotising pancreatitis. Gut 68, 1044–1051. 10.1136/gutjnl-2017-314657 (2019).29950344 10.1136/gutjnl-2017-314657
5. Bang JY Wilcox CM Arnoletti JP Varadarajulu S Superiority of endoscopic interventions over minimally invasive surgery for infected necrotizing pancreatitis: meta-analysis of randomized trials Dig. Endosc 2020 32 298 308 10.1111/den.13470 31220368
Bang, J. Y., Wilcox, C. M., Arnoletti, J. P. & Varadarajulu, S. Superiority of endoscopic interventions over minimally invasive surgery for infected necrotizing pancreatitis: meta-analysis of randomized trials. Dig. Endosc. 32, 298–308. 10.1111/den.13470 (2020).31220368 10.1111/den.13470
6. Staubli SM Oertli D Nebiker CA Assessing the severity of acute pancreatitis (ASAP) in Switzerland: a nationwide survey on severity assessment in daily clinical practice Pancreatology 2017 17 356 363 10.1016/j.pan.2017.02.006 28284583
Staubli, S. M., Oertli, D. & Nebiker, C. A. Assessing the severity of acute pancreatitis (ASAP) in Switzerland: a nationwide survey on severity assessment in daily clinical practice. Pancreatology 17, 356–363. 10.1016/j.pan.2017.02.006 (2017).28284583 10.1016/j.pan.2017.02.006
7. Xiao B Xu HB Jiang ZQ Zhang J Zhang XM Current concepts for the diagnosis of acute pancreatitis by multiparametric magnetic resonance imaging Quant. Imaging Med. Surg. 2019 9 1973 1985 10.21037/qims.2019.11.10 31929970
Xiao, B., Xu, H. B., Jiang, Z. Q., Zhang, J. & Zhang, X. M. Current concepts for the diagnosis of acute pancreatitis by multiparametric magnetic resonance imaging. Quant. Imaging Med. Surg. 9, 1973–1985. 10.21037/qims.2019.11.10 (2019).31929970 10.21037/qims.2019.11.10
8. Arif A Jaleel F Rashid K Accuracy of BISAP score in prediction of severe acute pancreatitis Pak J. Med. Sci. 2019 35 1008 1012 10.12669/pjms.35.4.1286 31372133
Arif, A., Jaleel, F. & Rashid, K. Accuracy of BISAP score in prediction of severe acute pancreatitis. Pak J. Med. Sci. 35, 1008–1012. 10.12669/pjms.35.4.1286 (2019).31372133 10.12669/pjms.35.4.1286
9. Lim J Kim J Koo SH Kwon GC Comparison of triglyceride glucose index, and related parameters to predict insulin resistance in Korean adults: an analysis of the 2007–2010 Korean National Health and Nutrition Examination Survey PLoS One 2019 14 e0212963 10.1371/journal.pone.0212963 30845237
Lim, J., Kim, J., Koo, S. H. & Kwon, G. C. Comparison of triglyceride glucose index, and related parameters to predict insulin resistance in Korean adults: an analysis of the 2007–2010 Korean National Health and Nutrition Examination Survey. PLoS One 14, e0212963. 10.1371/journal.pone.0212963 (2019).30845237 10.1371/journal.pone.0212963
10. Cho SK Huh JH Yoo JS Kim JW Lee K J. HOMA-estimated insulin resistance as an independent prognostic factor in patients with acute pancreatitis Sci. Rep. 2019 9 14894 10.1038/s41598-019-51466-5 31624312
Cho, S. K., Huh, J. H., Yoo, J. S., Kim, J. W. & Lee, K. J. HOMA-estimated insulin resistance as an independent prognostic factor in patients with acute pancreatitis. Sci. Rep. 9, 14894. 10.1038/s41598-019-51466-5 (2019).31624312 10.1038/s41598-019-51466-5
11. Su J Triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China Cardiovasc. Diabetol. 2022 21 96 10.1186/s12933-022-01523-7 35668496
Su, J. et al. Triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with coronary heart disease: a RCSCD-TCM study in China. Cardiovasc. Diabetol. 21, 96. 10.1186/s12933-022-01523-7 (2022).35668496 10.1186/s12933-022-01523-7
12. Boden G Obesity, insulin resistance and free fatty acids Curr. Opin. Endocrinol. Diabetes Obes. 2011 18 139 143 10.1097/MED.0b013e3283444b09 21297467
Boden, G. Obesity, insulin resistance and free fatty acids. Curr. Opin. Endocrinol. Diabetes Obes. 18, 139–143. 10.1097/MED.0b013e3283444b09 (2011).21297467 10.1097/MED.0b013e3283444b09
13. Er LK Triglyceride glucose-body Mass Index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals PLoS One 2016 11 e0149731 10.1371/journal.pone.0149731 26930652
Er, L. K. et al. Triglyceride glucose-body Mass Index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals. PLoS One 11, e0149731. 10.1371/journal.pone.0149731 (2016).26930652 10.1371/journal.pone.0149731
14. Du Z Xing L Lin M Sun Y Estimate of prevalent ischemic stroke from triglyceride glucose-body mass index in the general population BMC Cardiovasc. Disord 2020 20 483 10.1186/s12872-020-01768-8 33183220
Du, Z., Xing, L., Lin, M. & Sun, Y. Estimate of prevalent ischemic stroke from triglyceride glucose-body mass index in the general population. BMC Cardiovasc. Disord. 20, 483. 10.1186/s12872-020-01768-8 (2020).33183220 10.1186/s12872-020-01768-8
15. Dou J Association between triglyceride glucose-body mass and one-year all-cause mortality of patients with heart failure: a retrospective study utilizing the MIMIC-IV database Cardiovasc. Diabetol. 2023 22 309 10.1186/s12933-023-02047-4 37940979
Dou, J. et al. Association between triglyceride glucose-body mass and one-year all-cause mortality of patients with heart failure: a retrospective study utilizing the MIMIC-IV database. Cardiovasc. Diabetol. 22, 309. 10.1186/s12933-023-02047-4 (2023).37940979 10.1186/s12933-023-02047-4
16. Cheng Y Association between triglyceride glucose-body mass index and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: a retrospective study Cardiovasc. Diabetol. 2023 22 75 10.1186/s12933-023-01794-8 36997935
Cheng, Y. et al. Association between triglyceride glucose-body mass index and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: a retrospective study. Cardiovasc. Diabetol. 22, 75. 10.1186/s12933-023-01794-8 (2023).36997935 10.1186/s12933-023-01794-8
17. Johnson AEW MIMIC-IV, a freely accessible electronic health record dataset Sci. Data 2023 10 1 10.1038/s41597-022-01899-x 36596836
Johnson, A. E. W. et al. MIMIC-IV, a freely accessible electronic health record dataset. Sci. Data 10, 1. 10.1038/s41597-022-01899-x (2023).36596836 10.1038/s41597-022-01899-x
18. Le Gall JR Lemeshow S Saulnier F A new simplified Acute Physiology score (SAPS II) based on a European/North American multicenter study JAMA 1993 270 2957 2963 10.1001/jama.270.24.2957 8254858
Le Gall, J. R., Lemeshow, S. & Saulnier, F. A new simplified Acute Physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270, 2957–2963. 10.1001/jama.270.24.2957 (1993).8254858 10.1001/jama.270.24.2957
19. Juneja, D., Gopal, P. B. & Ravula, M. Scoring systems in acute pancreatitis: which one to use in intensive care units? J. Crit. Care 25 358.e359–358.e315 (2010).
20. Yang X Association of the triglyceride glucose-body mass index with the extent of coronary artery disease in patients with acute coronary syndromes Cardiovasc. Diabetol. 2024 23 24 10.1186/s12933-024-02124-2 38218893
Yang, X. et al. Association of the triglyceride glucose-body mass index with the extent of coronary artery disease in patients with acute coronary syndromes. Cardiovasc. Diabetol. 23, 24. 10.1186/s12933-024-02124-2 (2024).38218893 10.1186/s12933-024-02124-2
21. Lyu L Association between triglyceride glucose-body mass index and long-term adverse outcomes of heart failure patients with coronary heart disease Cardiovasc. Diabetol. 2024 23 162 10.1186/s12933-024-02213-2 38724999
Lyu, L. et al. Association between triglyceride glucose-body mass index and long-term adverse outcomes of heart failure patients with coronary heart disease. Cardiovasc. Diabetol. 23, 162. 10.1186/s12933-024-02213-2 (2024).38724999 10.1186/s12933-024-02213-2
22. Li F Association between the cumulative average triglyceride glucose-body mass index and cardiovascular disease incidence among the middle-aged and older population: a prospective nationwide cohort study in China Cardiovasc. Diabetol. 2024 23 16 10.1186/s12933-023-02114-w 38184577
Li, F. et al. Association between the cumulative average triglyceride glucose-body mass index and cardiovascular disease incidence among the middle-aged and older population: a prospective nationwide cohort study in China. Cardiovasc. Diabetol. 23, 16. 10.1186/s12933-023-02114-w (2024).38184577 10.1186/s12933-023-02114-w
23. Huo RR Zhai L Liao Q You XM Changes in the triglyceride glucose-body mass index estimate the risk of stroke in middle-aged and older Chinese adults: a nationwide prospective cohort study Cardiovasc. Diabetol. 2023 22 254 10.1186/s12933-023-01983-5 37716947
Huo, R. R., Zhai, L., Liao, Q. & You, X. M. Changes in the triglyceride glucose-body mass index estimate the risk of stroke in middle-aged and older Chinese adults: a nationwide prospective cohort study. Cardiovasc. Diabetol. 22, 254. 10.1186/s12933-023-01983-5 (2023).37716947 10.1186/s12933-023-01983-5
24. Shao Y Link between triglyceride-glucose-body mass index and future stroke risk in middle-aged and elderly Chinese: a nationwide prospective cohort study Cardiovasc. Diabetol. 2024 23 81 10.1186/s12933-024-02165-7 38402161
Shao, Y. et al. Link between triglyceride-glucose-body mass index and future stroke risk in middle-aged and elderly Chinese: a nationwide prospective cohort study. Cardiovasc. Diabetol. 23, 81. 10.1186/s12933-024-02165-7 (2024).38402161 10.1186/s12933-024-02165-7
25. Hu Y Zhao Y Zhang J Li C The association between triglyceride glucose-body mass index and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study from MIMIC-IV database Cardiovasc. Diabetol. 2024 23 64 10.1186/s12933-024-02153-x 38341579
Hu, Y., Zhao, Y., Zhang, J. & Li, C. The association between triglyceride glucose-body mass index and all-cause mortality in critically ill patients with atrial fibrillation: a retrospective study from MIMIC-IV database. Cardiovasc. Diabetol. 23, 64. 10.1186/s12933-024-02153-x (2024).38341579 10.1186/s12933-024-02153-x
26. Huang Y Li Z Yin X Long-term survival in stroke patients: insights into triglyceride-glucose body mass index from ICU data Cardiovasc. Diabetol. 2024 23 137 10.1186/s12933-024-02231-0 38664780
Huang, Y., Li, Z. & Yin, X. Long-term survival in stroke patients: insights into triglyceride-glucose body mass index from ICU data. Cardiovasc. Diabetol. 23, 137. 10.1186/s12933-024-02231-0 (2024).38664780 10.1186/s12933-024-02231-0
27. Mikolasevic I Metabolic syndrome and acute pancreatitis Eur. J. Intern. Med. 2016 32 79 83 10.1016/j.ejim.2016.04.004 27157403
Mikolasevic, I. et al. Metabolic syndrome and acute pancreatitis. Eur. J. Intern. Med. 32, 79–83. 10.1016/j.ejim.2016.04.004 (2016).27157403 10.1016/j.ejim.2016.04.004
28. Lee YH Pratley RE The evolving role of inflammation in obesity and the metabolic syndrome Curr. Diab Rep. 2005 5 70 75 10.1007/s11892-005-0071-7 15663921
Lee, Y. H. & Pratley, R. E. The evolving role of inflammation in obesity and the metabolic syndrome. Curr. Diab Rep. 5, 70–75. 10.1007/s11892-005-0071-7 (2005).15663921 10.1007/s11892-005-0071-7
29. Shen Z Wang X Zhen Z Wang Y Sun P Metabolic syndrome components and acute pancreatitis: a case-control study in China BMC Gastroenterol. 2021 21 17 10.1186/s12876-020-01579-3 33407178
Shen, Z., Wang, X., Zhen, Z., Wang, Y. & Sun, P. Metabolic syndrome components and acute pancreatitis: a case-control study in China. BMC Gastroenterol. 21, 17. 10.1186/s12876-020-01579-3 (2021).33407178 10.1186/s12876-020-01579-3
30. Huh JH Diabetes mellitus is associated with mortality in acute pancreatitis J. Clin. Gastroenterol. 2018 52 178 183 10.1097/mcg.0000000000000783 28009683
Huh, J. H. et al. Diabetes mellitus is associated with mortality in acute pancreatitis. J. Clin. Gastroenterol. 52, 178–183. 10.1097/mcg.0000000000000783 (2018).28009683 10.1097/mcg.0000000000000783
31. Krishna SG Morbid obesity is associated with adverse clinical outcomes in acute pancreatitis: a propensity-matched study Am. J. Gastroenterol. 2015 110 1608 1619 10.1038/ajg.2015.343 26482857
Krishna, S. G. et al. Morbid obesity is associated with adverse clinical outcomes in acute pancreatitis: a propensity-matched study. Am. J. Gastroenterol. 110, 1608–1619. 10.1038/ajg.2015.343 (2015).26482857 10.1038/ajg.2015.343
32. Zhang M Cumulative increased risk of incident type 2 diabetes mellitus with increasing triglyceride glucose index in normal-weight people: the rural Chinese cohort study Cardiovasc. Diabetol. 2017 16 30 10.1186/s12933-017-0514-x 28249577
Zhang, M. et al. Cumulative increased risk of incident type 2 diabetes mellitus with increasing triglyceride glucose index in normal-weight people: the rural Chinese cohort study. Cardiovasc. Diabetol. 16, 30. 10.1186/s12933-017-0514-x (2017).28249577 10.1186/s12933-017-0514-x
33. Navina S Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity Sci. Transl. Med. 2011 3 107ra110 10.1126/scitranslmed.3002573 22049070
Navina, S. et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci. Transl. Med. 3, 107ra110. 10.1126/scitranslmed.3002573 (2011).22049070 10.1126/scitranslmed.3002573
34. Patel K Lipolysis of visceral adipocyte triglyceride by pancreatic lipases converts mild acute pancreatitis to severe pancreatitis independent of necrosis and inflammation Am. J. Pathol. 2015 185 808 819 10.1016/j.ajpath.2014.11.019 25579844
Patel, K. et al. Lipolysis of visceral adipocyte triglyceride by pancreatic lipases converts mild acute pancreatitis to severe pancreatitis independent of necrosis and inflammation. Am. J. Pathol. 185, 808–819. 10.1016/j.ajpath.2014.11.019 (2015).25579844 10.1016/j.ajpath.2014.11.019
35. Tello-Flores, V. A. et al. Role of long non-coding RNAs and the Molecular mechanisms involved in insulin resistance. Int. J. Mol. Sci. 22. 10.3390/ijms22147256 (2021).
36. Tao LC Xu JN Wang TT Hua F Li JJ Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations Cardiovasc. Diabetol. 2022 21 68 10.1186/s12933-022-01511-x 35524263
Tao, L. C., Xu, J. N., Wang, T. T., Hua, F. & Li, J. J. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc. Diabetol. 21, 68. 10.1186/s12933-022-01511-x (2022).35524263 10.1186/s12933-022-01511-x
37. Guerrero-Romero F The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp J. Clin. Endocrinol. Metab. 2010 95 3347 3351 10.1210/jc.2010-0288 20484475
Guerrero-Romero, F. et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J. Clin. Endocrinol. Metab. 95, 3347–3351. 10.1210/jc.2010-0288 (2010).20484475 10.1210/jc.2010-0288
